CL2018000803A1 - Composiciones y métodos para inhibir la expresión génica de lpa. - Google Patents
Composiciones y métodos para inhibir la expresión génica de lpa.Info
- Publication number
- CL2018000803A1 CL2018000803A1 CL2018000803A CL2018000803A CL2018000803A1 CL 2018000803 A1 CL2018000803 A1 CL 2018000803A1 CL 2018000803 A CL2018000803 A CL 2018000803A CL 2018000803 A CL2018000803 A CL 2018000803A CL 2018000803 A1 CL2018000803 A1 CL 2018000803A1
- Authority
- CL
- Chile
- Prior art keywords
- gene expression
- compositions
- methods
- lpa
- agents
- Prior art date
Links
- 230000014509 gene expression Effects 0.000 title abstract 3
- 101150091521 lpa gene Proteins 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title 1
- 230000009368 gene silencing by RNA Effects 0.000 abstract 5
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 102100040214 Apolipoprotein(a) Human genes 0.000 abstract 3
- 101710115418 Apolipoprotein(a) Proteins 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 210000005229 liver cell Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3517—Marker; Tag
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se describen los agentes de interferencia de ARN (ARNi) y los conjugados de los agentes ARNi para inhibir la expresión del gen LPA (apo(a)). También se describen composiciones farmacéuticas que comprenden uno o más agentes de ARNi de LPA opcionalmente con uno o más agentes terapéuticos. La entrega de los agentes de ARNi de LPA descritos a las células hepáticas in vivo proporciona la inhibición de la expresión del gen LPA y el tratamiento de enfermedades cardiovasculares y cardiovasculares relacionadas.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562235816P | 2015-10-01 | 2015-10-01 | |
| US201662346304P | 2016-06-06 | 2016-06-06 | |
| US201662383221P | 2016-09-02 | 2016-09-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018000803A1 true CL2018000803A1 (es) | 2018-08-31 |
Family
ID=58424351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018000803A CL2018000803A1 (es) | 2015-10-01 | 2018-03-28 | Composiciones y métodos para inhibir la expresión génica de lpa. |
Country Status (37)
| Country | Link |
|---|---|
| US (3) | US9932586B2 (es) |
| EP (2) | EP3356529B1 (es) |
| JP (4) | JP6991966B2 (es) |
| KR (1) | KR20180052703A (es) |
| CN (1) | CN108368506A (es) |
| AU (2) | AU2016331084B2 (es) |
| BR (1) | BR112018006489A2 (es) |
| CA (1) | CA3000397A1 (es) |
| CL (1) | CL2018000803A1 (es) |
| CO (1) | CO2018003678A2 (es) |
| CR (1) | CR20180231A (es) |
| CY (1) | CY1125263T1 (es) |
| DK (1) | DK3356529T3 (es) |
| EA (1) | EA038478B1 (es) |
| ES (1) | ES2896298T3 (es) |
| HK (1) | HK1259063A1 (es) |
| HR (1) | HRP20211410T1 (es) |
| HU (1) | HUE055942T2 (es) |
| IL (3) | IL300438A (es) |
| JO (2) | JOP20210043A1 (es) |
| LT (1) | LT3356529T (es) |
| MA (1) | MA43347B1 (es) |
| MX (2) | MX2018003833A (es) |
| MY (1) | MY195796A (es) |
| PE (1) | PE20181139A1 (es) |
| PH (1) | PH12018500713A1 (es) |
| PL (1) | PL3356529T3 (es) |
| PT (1) | PT3356529T (es) |
| RS (1) | RS62523B1 (es) |
| SG (1) | SG10202008530TA (es) |
| SI (1) | SI3356529T1 (es) |
| TN (1) | TN2018000094A1 (es) |
| TW (2) | TWI784934B (es) |
| UA (1) | UA121998C2 (es) |
| UY (1) | UY36926A (es) |
| WO (1) | WO2017059223A2 (es) |
| ZA (1) | ZA202106265B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7718133B2 (en) | 2003-10-09 | 2010-05-18 | 3M Innovative Properties Company | Multilayer processing devices and methods |
| WO2017156012A1 (en) * | 2016-03-07 | 2017-09-14 | Arrowhead Pharmaceuticals, Inc. | Targeting ligands for therapeutic compounds |
| EP3506913A4 (en) * | 2016-09-02 | 2020-06-10 | Arrowhead Pharmaceuticals, Inc. | TARGETING LIGANDS |
| SI3607069T1 (sl) | 2017-04-05 | 2023-02-28 | Silence Therapeutics Gmbh | Produkti in sestavki |
| TN2019000308A1 (en) * | 2017-07-06 | 2021-05-07 | Arrowhead Pharmaceuticals Inc | RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE |
| TN2020000039A1 (en) * | 2017-09-11 | 2021-10-04 | Arrowhead Pharmaceuticals Inc | Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3) |
| PE20201287A1 (es) * | 2017-09-14 | 2020-11-24 | Arrowhead Pharmaceuticals Inc | Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso |
| WO2019079294A1 (en) * | 2017-10-17 | 2019-04-25 | Arrowhead Pharmaceuticals, Inc. | RNAI-BASED AGENTS AND COMPOSITIONS FOR INHIBITING ASIALOGLYCOPROTEIN RECEPTOR 1 RECEPTOR 1 |
| EP3483270A1 (en) * | 2017-11-13 | 2019-05-15 | Silence Therapeutics GmbH | Products and compositions |
| IL274503B1 (en) * | 2017-11-13 | 2024-06-01 | Silence Therapeutics Gmbh | Nucleic acids to inhibit LPA expression in the cell |
| CA3109553A1 (en) * | 2018-09-19 | 2020-03-26 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of 17beta-hsd type 13 (hsd17b13), compositions thereof, and methods of use |
| PT3880818T (pt) * | 2019-05-14 | 2022-12-06 | Silence Therapeutics Gmbh | Ácidos nucleicos para inibir a expressão de lpa numa célula |
| JP2023504744A (ja) | 2019-12-09 | 2023-02-06 | アムジエン・インコーポレーテツド | ＬＰＡ発現を阻害するためのＲＮＡｉコンストラクト及び方法 |
| EP4192954A1 (en) | 2020-08-05 | 2023-06-14 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting lpa expression |
| US20240035029A1 (en) * | 2020-10-16 | 2024-02-01 | Sanofi | Rna compositions and methods for inhibiting lipoprotein(a) |
| KR20230104200A (ko) | 2020-11-05 | 2023-07-07 | 암젠 인크 | LPA-표적화된 RNAi 작제물을 이용하여 죽상경화성 심혈관질환을 치료하는 방법 |
| WO2022121959A1 (zh) * | 2020-12-09 | 2022-06-16 | 纳肽得有限公司 | siRNA分子及其在治疗冠状动脉疾病中的应用 |
| EP4237561A1 (en) | 2020-12-23 | 2023-09-06 | Argonaute Rna Limited | Treatment of cardiovascular disease |
| US11649260B2 (en) | 2021-06-18 | 2023-05-16 | Hongene Biotech Corporation | Functionalized N-acetylgalactosamine nucleosides |
| US11692001B2 (en) | 2021-08-30 | 2023-07-04 | Hongene Biotech Corporation | Functionalized n-acetylgalactosamine analogs |
| EP4402263A2 (en) | 2021-09-14 | 2024-07-24 | Argonaute Rna Limited | Treatment of cardiovascular disease |
| CN116801886A (zh) * | 2021-09-18 | 2023-09-22 | 上海金中锘美生物医药科技有限公司 | Lpa抑制剂及其用途 |
| WO2023114746A1 (en) | 2021-12-15 | 2023-06-22 | Hongene Biotech Corporation | Functionalized n-acetylgalactosamine analogs |
| CN114703184B (zh) * | 2022-03-11 | 2024-06-18 | 厦门甘宝利生物医药有限公司 | Lpa抑制剂及其用途 |
| WO2024032681A1 (zh) * | 2022-08-11 | 2024-02-15 | 益杰立科(上海)生物科技有限公司 | 一种表观编辑靶点的方法及用途 |
| CN115851723B (zh) * | 2022-10-24 | 2023-10-03 | 厦门甘宝利生物医药有限公司 | 一种抑制lpa基因表达的rna抑制剂及其应用 |
| WO2024151937A1 (en) * | 2023-01-13 | 2024-07-18 | Eli Lilly And Company | Therapeutic oligonucleotide-containing pharmaceutical compositions and dosing regimens using the same |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL9201440A (nl) | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennaire clusterglycosiden, hun bereiding en toepassing. |
| US5599706A (en) | 1994-09-23 | 1997-02-04 | Stinchcomb; Dan T. | Ribozymes targeted to apo(a) mRNA |
| ATE408699T1 (de) | 1999-03-10 | 2008-10-15 | Phogen Ltd | Verabreichung von nukleinsäuren und proteinen an zellen |
| CZ302719B6 (cs) * | 2000-12-01 | 2011-09-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití |
| US7259150B2 (en) | 2001-08-07 | 2007-08-21 | Isis Pharmaceuticals, Inc. | Modulation of apolipoprotein (a) expression |
| US7227014B2 (en) | 2001-08-07 | 2007-06-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein (a) expression |
| JP2006523209A (ja) | 2003-03-12 | 2006-10-12 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ | アペリン組成物によって血管新生を調節するための方法 |
| US8084599B2 (en) | 2004-03-15 | 2011-12-27 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| EP2061443A4 (en) | 2006-08-18 | 2013-07-24 | Arrowhead Res Corp | POLYCONJUGATE FOR IN VIVO ADMINISTRATION OF POLYNUCLEOTIDES |
| CA3151965A1 (en) | 2008-12-18 | 2010-07-15 | Dicerna Pharmaceuticals, Inc. | Extended dicer substrate agents and methods for the specific inhibition of gene expression |
| US20100249214A1 (en) | 2009-02-11 | 2010-09-30 | Dicerna Pharmaceuticals | Multiplex dicer substrate rna interference molecules having joining sequences |
| SG183374A1 (en) | 2010-02-24 | 2012-09-27 | Arrowhead Res Corp | Compositions for targeted delivery of sirna |
| WO2011141703A1 (en) * | 2010-05-12 | 2011-11-17 | Protiva Biotherapeutics Inc. | Compositions and methods for silencing apolipoprotein b |
| US8501930B2 (en) * | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
| JP2014504295A (ja) | 2010-12-17 | 2014-02-20 | アローヘッド リサーチ コーポレイション | ｓｉＲＮＡ用ガラクトースクラスター−薬物動態調節剤標的指向部分 |
| PE20140198A1 (es) | 2010-12-29 | 2014-02-21 | Arrowhead Res Corp | Conjugados de suministro de polinucleotidos in vivo que tienen acoplamientos sensibles a enzima |
| KR20140051357A (ko) | 2011-08-26 | 2014-04-30 | 애로우헤드 리서치 코오포레이션 | Ｉｎ Ｖｉｖｏ 핵산 전달용 폴리(비닐 에스테르) 고분자 |
| SI3301177T1 (sl) * | 2011-11-18 | 2020-07-31 | Alnylam Pharmaceuticals, Inc. | Sredstva RNAi, sestavki in postopki njihove uporabe za zdravljenje s transtiretinom (TTR) povezanih bolezni |
| US8933047B2 (en) | 2012-04-18 | 2015-01-13 | Arrowhead Madison Inc. | Poly(acrylate) polymers for in vivo nucleic acid delivery |
| DK2855500T3 (da) | 2012-05-24 | 2020-09-14 | Ionis Pharmaceuticals Inc | Fremgangsmåder og sammensætninger til modulering af apolipoprotein (A)-ekspression |
| RU2650510C2 (ru) | 2013-05-01 | 2018-04-16 | Ионис Фармасьютикалз, Инк. | Композиции и способы модулирования экспрессии аполипопротеина c-iii |
| US20160272970A1 (en) | 2015-03-17 | 2016-09-22 | Arrowhead Madison Inc. | RNA Interference Agents |
| EA201792103A1 (ru) | 2015-05-29 | 2018-06-29 | Эрроухэд Фармасьютикалз, Инк. | Композиции и способы для ингибирования экспрессии генов hif2альфа |
| CN108138182B (zh) * | 2015-07-31 | 2022-08-19 | 阿尔尼拉姆医药品有限公司 | 甲状腺素运载蛋白(TTR)iRNA组合物及其治疗或预防TTR相关疾病的使用方法 |
| WO2017156012A1 (en) | 2016-03-07 | 2017-09-14 | Arrowhead Pharmaceuticals, Inc. | Targeting ligands for therapeutic compounds |
-
2015
- 2015-10-01 JO JOP/2021/0043A patent/JOP20210043A1/ar unknown
-
2016
- 2016-09-28 JO JOP/2016/0211A patent/JOP20160211B1/ar active
- 2016-09-30 TW TW105131823A patent/TWI784934B/zh active
- 2016-09-30 RS RS20211351A patent/RS62523B1/sr unknown
- 2016-09-30 US US15/281,309 patent/US9932586B2/en active Active
- 2016-09-30 PT PT168526952T patent/PT3356529T/pt unknown
- 2016-09-30 CR CR20180231A patent/CR20180231A/es unknown
- 2016-09-30 AU AU2016331084A patent/AU2016331084B2/en active Active
- 2016-09-30 UA UAA201804593A patent/UA121998C2/uk unknown
- 2016-09-30 BR BR112018006489-0A patent/BR112018006489A2/pt active Search and Examination
- 2016-09-30 CA CA3000397A patent/CA3000397A1/en active Pending
- 2016-09-30 TW TW111141660A patent/TWI836693B/zh active
- 2016-09-30 IL IL300438A patent/IL300438A/en unknown
- 2016-09-30 ES ES16852695T patent/ES2896298T3/es active Active
- 2016-09-30 PE PE2018000487A patent/PE20181139A1/es unknown
- 2016-09-30 WO PCT/US2016/054729 patent/WO2017059223A2/en active Application Filing
- 2016-09-30 LT LTEPPCT/US2016/054729T patent/LT3356529T/lt unknown
- 2016-09-30 KR KR1020187010095A patent/KR20180052703A/ko not_active Application Discontinuation
- 2016-09-30 MX MX2018003833A patent/MX2018003833A/es unknown
- 2016-09-30 TN TNP/2018/000094A patent/TN2018000094A1/en unknown
- 2016-09-30 UY UY0001036926A patent/UY36926A/es unknown
- 2016-09-30 EP EP16852695.2A patent/EP3356529B1/en active Active
- 2016-09-30 HR HRP20211410TT patent/HRP20211410T1/hr unknown
- 2016-09-30 SI SI201631374T patent/SI3356529T1/sl unknown
- 2016-09-30 CN CN201680057095.8A patent/CN108368506A/zh active Pending
- 2016-09-30 DK DK16852695.2T patent/DK3356529T3/da active
- 2016-09-30 PL PL16852695T patent/PL3356529T3/pl unknown
- 2016-09-30 EA EA201890864A patent/EA038478B1/ru unknown
- 2016-09-30 HU HUE16852695A patent/HUE055942T2/hu unknown
- 2016-09-30 SG SG10202008530TA patent/SG10202008530TA/en unknown
- 2016-09-30 EP EP21191363.7A patent/EP4029941A1/en active Pending
- 2016-09-30 JP JP2018516738A patent/JP6991966B2/ja active Active
- 2016-09-30 MY MYPI2018000440A patent/MY195796A/en unknown
-
2017
- 2017-04-06 MA MA43347A patent/MA43347B1/fr unknown
-
2018
- 2018-02-21 US US15/901,810 patent/US10662427B2/en active Active
- 2018-03-25 IL IL258333A patent/IL258333B/en unknown
- 2018-03-27 MX MX2022013010A patent/MX2022013010A/es unknown
- 2018-03-28 CL CL2018000803A patent/CL2018000803A1/es unknown
- 2018-03-28 PH PH12018500713A patent/PH12018500713A1/en unknown
- 2018-04-05 CO CONC2018/0003678A patent/CO2018003678A2/es unknown
-
2019
- 2019-01-29 HK HK19101563.4A patent/HK1259063A1/zh unknown
-
2020
- 2020-05-06 US US16/867,925 patent/US20200263179A1/en active Pending
-
2021
- 2021-03-12 JP JP2021039949A patent/JP7116212B2/ja active Active
- 2021-08-30 ZA ZA2021/06265A patent/ZA202106265B/en unknown
- 2021-11-08 CY CY20211100962T patent/CY1125263T1/el unknown
-
2022
- 2022-02-13 IL IL290566A patent/IL290566B2/en unknown
- 2022-06-15 JP JP2022096415A patent/JP7442574B2/ja active Active
- 2022-12-05 AU AU2022283623A patent/AU2022283623A1/en active Pending
-
2023
- 2023-11-27 JP JP2023199857A patent/JP2024009262A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018000803A1 (es) | Composiciones y métodos para inhibir la expresión génica de lpa. | |
| DOP2019000005A (es) | 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2 | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| ECSP20017905A (es) | AGENTES DE iARN Y COMPOSICIONES PARA INHIBIR LA EXPRESIÓN DE LA APOLIPOPROTEÍNA C-III (APOC3) | |
| GT201700167A (es) | Terapias de combinación para el tratamiento de cánceres. | |
| UY36285A (es) | Compuestos que inhiben la proteína mcl-1 | |
| CR20160237A (es) | Derivados de la carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
| DOP2012000257A (es) | Derivados del acido 1-amino-2-ciclopropiletilboronico | |
| UY37098A (es) | Moduladores de ror-gamma | |
| CO2019009722A2 (es) | Dendrímeros terapéuticos | |
| EA201792103A1 (ru) | Композиции и способы для ингибирования экспрессии генов hif2альфа | |
| CO2018002198A2 (es) | Composiciones farmacéuticas que comprenden un compuesto oligomérico para modular la expresión de apolipoproteína (a) | |
| ECSP20000655A (es) | AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO | |
| AR106227A1 (es) | COMPOSICIONES Y MÉTODOS PARA INHIBIR LA EXPRESIÓN GÉNICA DEL GEN DE LA APOLIPOPROTEÍNA APO(a) (LPA) | |
| DOP2014000221A (es) | Métodos para tratar el cáncer usando inhibidor de pi3k e inhibidor de mek | |
| AR113014A1 (es) | AGENTES DE iARN Y COMPOSICIONES PARA INHIBIR LA EXPRESIÓN DE LA APOLIPOPROTEÍNA C-III (APOC3) | |
| AR112754A1 (es) | AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE a-ENaC Y MÉTODOS DE USO | |
| AR105611A1 (es) | TERAPIA ARNi PARA INFECCIÓN POR VIRUS DE HEPATITIS B | |
| BR112017021114A8 (pt) | Compostos heterocíclicos como inibidores de lsd1 | |
| AR096390A1 (es) | COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO | |
| CU20120052A7 (es) | Derivados de pirazol que modulan estearoil-coa-desaturasa | |
| AR090580A1 (es) | Composiciones farmaceuticas para terapia combinada |